CompletedPhase 1NCT00588991

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

Studying Acute erythroid leukemia

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Cancer Institute (NCI)
Principal Investigator: Keith W Pratz
Johns Hopkins University/Sidney Kimmel Cancer Center
Intervention: Carboplatin(drug)
Enrollment: 12 enrolled
Eligibility: 18 years · All sexes
Timeline: 2008 – 2016

Study locations (2)

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00588991 on ClinicalTrials.gov

Other trials for Acute erythroid leukemia

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2NCT00658814
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)

See all trials for Acute erythroid leukemia →

← Back to all trials